Abbott Will Stop Sales of Absorb Bioresorbable Vascular Scaffold System


September 8, 2017—Abbott Vascular announced that it will stop selling the first-generation Absorb bioresorbable vascular scaffold system and the Absorb GT1 bioresorbable vascular scaffold system in all countries as of September 14, 2017. The company attributed the decision to low commercial sales.

Abbott Vascular advised that physicians can implant Absorb with their available inventory if they choose to do so. In Europe, this applies only to centers currently participating in approved clinical studies. Abbott will continue to follow patients in existing clinical studies per protocols to assess long-term outcomes after the scaffold has dissolved.

For more information, physicians may contact their local Abbott Vascular representative or customer service team.

On the company's online product page, Abbott Vascular stated, "We recognize that bioresorbable scaffold technologies offer patients the possibility of life without permanent metallic implants, and we will continue to work on a next-generation device while monitoring long-term outcomes after stent resorption in current Absorb trials."


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.